SE430502B - Sett att framstella nya substituerade imidazolidiner - Google Patents

Sett att framstella nya substituerade imidazolidiner

Info

Publication number
SE430502B
SE430502B SE7610859A SE7610859A SE430502B SE 430502 B SE430502 B SE 430502B SE 7610859 A SE7610859 A SE 7610859A SE 7610859 A SE7610859 A SE 7610859A SE 430502 B SE430502 B SE 430502B
Authority
SE
Sweden
Prior art keywords
want
make new
new substituted
substituted imidazolidines
imidazolidines
Prior art date
Application number
SE7610859A
Other languages
English (en)
Swedish (sv)
Other versions
SE7610859L (sv
Inventor
J Perronnet
P Girault
C Bonne
Original Assignee
Roussel Uclaf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf filed Critical Roussel Uclaf
Publication of SE7610859L publication Critical patent/SE7610859L/xx
Publication of SE430502B publication Critical patent/SE430502B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
SE7610859A 1975-10-29 1976-09-30 Sett att framstella nya substituerade imidazolidiner SE430502B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7533084A FR2329276A1 (fr) 1975-10-29 1975-10-29 Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant

Publications (2)

Publication Number Publication Date
SE7610859L SE7610859L (sv) 1977-04-30
SE430502B true SE430502B (sv) 1983-11-21

Family

ID=9161795

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7610859A SE430502B (sv) 1975-10-29 1976-09-30 Sett att framstella nya substituerade imidazolidiner

Country Status (18)

Country Link
US (1) US4097578A (US07655688-20100202-C00217.png)
JP (1) JPS6011701B2 (US07655688-20100202-C00217.png)
AU (1) AU500542B2 (US07655688-20100202-C00217.png)
BE (1) BE847742A (US07655688-20100202-C00217.png)
BG (1) BG60533B2 (US07655688-20100202-C00217.png)
CA (1) CA1086751A (US07655688-20100202-C00217.png)
CH (1) CH599164A5 (US07655688-20100202-C00217.png)
DE (1) DE2649925C2 (US07655688-20100202-C00217.png)
DK (1) DK152125C (US07655688-20100202-C00217.png)
ES (1) ES452746A1 (US07655688-20100202-C00217.png)
FR (1) FR2329276A1 (US07655688-20100202-C00217.png)
GB (1) GB1518444A (US07655688-20100202-C00217.png)
GE (1) GEP19970948B (US07655688-20100202-C00217.png)
IE (1) IE43875B1 (US07655688-20100202-C00217.png)
LU (2) LU76085A1 (US07655688-20100202-C00217.png)
NL (2) NL187102C (US07655688-20100202-C00217.png)
SE (1) SE430502B (US07655688-20100202-C00217.png)
SU (1) SU596165A3 (US07655688-20100202-C00217.png)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MC1220A1 (fr) * 1977-10-28 1979-07-20 Hoffmann La Roche Nouveaux derives d'imidazolidine
IL55774A (en) * 1977-10-28 1982-04-30 Sparamedica Ag Pharmaceutical compositions containing urea derivatives,certain such novel derivatives and their manufacture
FI801184A (fi) * 1979-04-24 1980-10-25 Hoffmann La Roche Foerfarande foer framstaellning av imidazolidinderivat
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
WO1986001105A1 (en) * 1984-08-02 1986-02-27 Fernand Labrie Pharmaceutical composition for combination therapy of hormone dependent cancers
US4775660A (en) * 1984-08-02 1988-10-04 Fernand Labrie Treatment of breast cancer by combination therapy
US5084472A (en) * 1986-11-04 1992-01-28 Roussel Application of 1-(3'-trifluoromethyl-4'-nitrophenyl)-4,4'-dimethylimidazoline 2,5-dione in the treatment of hormone-dependent cancers other than that of the prostate
IT1214735B (it) * 1986-11-04 1990-01-18 Roussel Maestretti Spa Impiego di 1-(3'-trifluorometil 4'nitrofenil) 4,4-dimetilimidazolin2,5-dione per il trattamento di cancri ormonodipendenti diverso da quello della prostata
FR2619381B1 (fr) * 1987-08-13 1989-12-08 Roussel Uclaf Nouvelles imidazolidines substituees par un radical hydroxymethyle et un radical phenyl substitue, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant et un intermediaire pour leur preparation
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
FR2656302B1 (fr) * 1989-12-22 1992-05-07 Roussel Uclaf Nouveau procede de preparation de l'anandron et derives de l'anandron.
US5411981A (en) * 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2671348B1 (fr) * 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
FR2693461B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
USRE35956E (en) * 1991-01-09 1998-11-10 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
US6002016A (en) * 1991-12-20 1999-12-14 Rhone-Poulenc Agrochimie Fungicidal 2-imidazolin-5-ones and 2-imidazoline-5-thiones
FR2706456B1 (fr) 1993-06-18 1996-06-28 Rhone Poulenc Agrochimie Dérivés optiquement actifs de 2-imidazoline-5-ones et 2-imidazoline-5-thiones fongicides.
FR2685328B1 (fr) * 1991-12-20 1995-12-01 Rhone Poulenc Agrochimie Derives de 2-imidazoline-5-ones et 2-imidazoline-5-thiones fongicides.
FR2694290B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US6008370A (en) * 1992-11-25 1999-12-28 Rhone-Poulenc Agrochimie Fungicidal-2-alkoxy/haloalkoxy-1-(mono- or disubstituted)amino-4,4-disubstituted-2-imidazolin-5-ones
TW521073B (en) * 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2715402B1 (fr) * 1994-01-05 1996-10-04 Roussel Uclaf Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
FR2724169B1 (fr) * 1994-09-06 1997-01-03 Roussel Uclaf Nouvelles phenylimidazolidines eventuellement substituees, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
FR2725206B1 (fr) * 1994-09-29 1996-12-06 Roussel Uclaf Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US5656651A (en) * 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US7001911B2 (en) * 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
AU2001288213B2 (en) * 2000-06-28 2005-04-14 Bristol-Myers Squibb Company Selective androgen receptor modulators and methods for their identification, design and use
EP1854798A3 (en) 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US6953679B2 (en) 2000-09-19 2005-10-11 Bristol-Myers Squibb Company Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US7015253B2 (en) * 2001-07-10 2006-03-21 American Medical Systems, Inc. Regimen for treating prostate tissue and surgical kit for use in the regimen
ES2310622T3 (es) * 2001-12-19 2009-01-16 Bristol-Myers Squibb Company Compuestos heterociclicos condensados y analogos de los mismos, moduladores de la funcion de los receptores nucleares de hormonas.
FR2850652B1 (fr) * 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
US7354933B2 (en) * 2003-01-31 2008-04-08 Aventis Pharma Sa Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
MXPA06001751A (es) * 2003-08-22 2006-05-12 Ligand Pharm Inc Derivados de 6-cicloamino-2-quinolinona como compuestos moduladores de receptor de androgeno.
CA2546601A1 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
DE602004031881D1 (de) * 2003-12-19 2011-04-28 Univ California Verfahren und materialien zur beurteilung von prostatakrebstherapien
NZ550102A (en) * 2004-02-24 2010-10-29 Univ California Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives)
WO2005090282A1 (en) 2004-03-12 2005-09-29 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
JP5031568B2 (ja) * 2004-09-10 2012-09-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 選択的アンドロゲン受容体モジュレーター（ｓａｒｍｓ）としての新規なイミダゾリジン−２−オン誘導体
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
ES2535179T3 (es) 2005-05-13 2015-05-06 The Regents Of The University Of California Compuesto de diarilhidantoína como antagonistas de los receptores de andrógenos para el tratamiento de cáncer
KR101293935B1 (ko) * 2005-06-17 2013-08-08 리간드 파마슈티칼스 인코포레이티드 안드로겐 수용체 조절 화합물 및 방법
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
FR2896503B1 (fr) * 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
DK2368550T3 (da) 2006-03-27 2013-09-30 Univ California Androgenreceptormodulator til behandlingen af prostatakræft og androgenreceptor-associerede sygdomme
EP2439196A1 (en) 2006-03-29 2012-04-11 The Regents of The University of California Diarylthiohydantoin compounds for use in a method for the treatment of a hyperproliferative disorder
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
EP4238519A3 (en) 2007-01-02 2023-11-29 AquaBeam LLC Minimally invasive methods and devices for the treatment of prostate diseases
US9232959B2 (en) 2007-01-02 2016-01-12 Aquabeam, Llc Multi fluid tissue resection methods and devices
US20080245375A1 (en) * 2007-04-05 2008-10-09 Medtronic Vascular, Inc. Benign Prostatic Hyperplasia Treatments
UY31432A1 (es) 2007-10-26 2009-05-29 Compuestos de diarilhidantoina
WO2009111736A1 (en) 2008-03-06 2009-09-11 Aquabeam Llc Tissue ablation and cautery with optical energy carried in fluid stream
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
US9848904B2 (en) 2009-03-06 2017-12-26 Procept Biorobotics Corporation Tissue resection and treatment with shedding pulses
WO2016037137A1 (en) 2014-09-05 2016-03-10 Procept Biorobotics Corporation Physician controlled tissue resection integrated with treatment mapping of target organ images
FR2944524B1 (fr) 2009-04-17 2012-11-30 Ipsen Pharma Sas Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
SG10201501202TA (en) 2010-02-16 2015-04-29 Aragon Pharmaceuticals Inc Androgen Receptor Modulators And Uses Thereof
EP2672958A1 (en) 2011-02-08 2013-12-18 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
CN104203078B (zh) 2012-02-29 2018-04-20 普罗赛普特生物机器人公司 自动化图像引导的组织切除和处理
ES2836424T3 (es) 2012-09-26 2021-06-25 Aragon Pharmaceuticals Inc Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
EP2956070A4 (en) 2013-02-14 2016-12-07 Procept Biorobotics Corp METHOD AND DEVICE FOR AQUABLATION AQUABEAM EYE SURGERY
WO2014130932A2 (en) 2013-02-25 2014-08-28 Novartis Ag Novel androgen receptor mutation
BR112016005036A2 (pt) 2013-09-06 2020-04-07 Procept Biorobotics Corp aparelho para ressecção de tecido guiada por imagem automatizada
EP4070744A1 (en) 2014-06-30 2022-10-12 PROCEPT BioRobotics Corporation Fluid jet tissue resection and cold coagulation (aquablation) apparatus
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
EP3500310A1 (en) 2016-08-20 2019-06-26 FTF Pharma Private Limited Pharmaceutical composition comprising an androgen receptor inhibitor
CN107216290B (zh) * 2017-06-12 2021-03-16 陕西科技大学 一种3-丁基-5,5-二甲基海因咪唑季铵盐及其制备方法
EP3697398A1 (en) 2017-10-16 2020-08-26 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB997037A (en) * 1962-03-19 1965-06-30 Ici Ltd New hydrantoin derivatives
JPS4920973B1 (US07655688-20100202-C00217.png) * 1970-05-28 1974-05-29
JPS5136332B1 (US07655688-20100202-C00217.png) * 1970-12-09 1976-10-07
IL45459A (en) * 1973-09-03 1978-01-31 Ciba Geigy Ag 1-(dichlorofluoromethylthio)-3-phenyl-imidazolidine-2,4-dione derivatives their preparation and their use as bactericides and fungicides

Also Published As

Publication number Publication date
CH599164A5 (US07655688-20100202-C00217.png) 1978-05-12
AU1909576A (en) 1978-05-04
LU88282I2 (fr) 1994-05-04
DK152125B (da) 1988-02-01
FR2329276A1 (fr) 1977-05-27
BE847742A (fr) 1977-04-28
BG60533B2 (bg) 1995-07-28
GEP19970948B (en) 1997-04-18
SU596165A3 (ru) 1978-02-28
US4097578A (en) 1978-06-27
NL930079I1 (nl) 1993-09-16
IE43875L (en) 1977-04-29
NL7611576A (nl) 1977-05-03
CA1086751A (fr) 1980-09-30
NL187102B (nl) 1991-01-02
DK487476A (da) 1977-04-30
ES452746A1 (es) 1977-10-01
IE43875B1 (en) 1981-06-17
JPS6011701B2 (ja) 1985-03-27
DE2649925C2 (de) 1986-08-28
AU500542B2 (en) 1979-05-24
GB1518444A (en) 1978-07-19
LU76085A1 (US07655688-20100202-C00217.png) 1977-05-31
DE2649925A1 (de) 1977-05-12
NL930079I2 (nl) 1993-10-01
FR2329276B1 (US07655688-20100202-C00217.png) 1979-09-14
SE7610859L (sv) 1977-04-30
DK152125C (da) 1988-06-20
NL187102C (nl) 1991-06-03
JPS5257176A (en) 1977-05-11

Similar Documents

Publication Publication Date Title
SE430502B (sv) Sett att framstella nya substituerade imidazolidiner
SE436425B (sv) Sett att framstella nya spirolaktoner
SE432247B (sv) Sett att framstella dihydro-cyklosporin c
SE433222B (sv) Sett att framstella modifierad polysackarid
SE441528B (sv) Sett att framstella nya 3-kinolin-karboxylsyraderivat
SE7606280L (sv) Sett att framstella etrar
SE7607152L (sv) Sett att framstella nya 2-piperidinoalkyl-1,4-bensdioxaner
SE435928B (sv) Sett att framstella nya 3-aryl-oxazolidin-2-oner
SE430887B (sv) Sett att framstella vissa substituerade fenylguanidiner
SE418860B (sv) Sett att framstella nya 1-aryl-2-(1-imidazolyl)-alkyletrar och -tioetrar
SE420728B (sv) Sett att framstella piperazinyliminorifamyciner
SE425736B (sv) Sett att framstella kromanon-(4)
SE427111B (sv) Sett att framstella pilokarpiniumsalter
SE7602729L (sv) Sett att framstella nya indolylalkylpiperidiner
SE424991B (sv) Sett att framstella nya 5-fenyl-oxazolidinoner
SE436037B (sv) Sett att framstella nya 11-desoxi-prostaglandin-f?712-derivat
SE434842B (sv) Sett att framstella nya 7-amino-tiazolyl-acetamido-cefalosporansyraderivat
SE7705986L (sv) Sett att framstella nya aryltrifluoretyaminer
SE430156B (sv) Sett att framstella 2-subst-1-(omega-aminoalkoxi)-bensener
SE428930B (sv) Sett att framstella nya depa-stereoidestrar tillhorande ostran-serien
SE420690B (sv) Sett att kontinuerligt framstella vermeisolerande ledningsror
SE7509209L (sv) Sett att framstella nya kinolinderivat
SE7607171L (sv) Sett att framstella indolokinoliziner
SE412233B (sv) Sett att framstella nya fenotiazinderivat
SE7609666L (sv) Sett att framstella nya 5-aminometyltiazolderivat

Legal Events

Date Code Title Description
SPCF Application for supplementary protection certificate filed

Free format text: 7610859

SPCG Supplementary protection certificate granted

Free format text: 7610859, EXPIRES: 20010930

NAL Patent in force

Ref document number: 7610859-6

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 7610859-6

Format of ref document f/p: F